{"analyses":[{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1191","paramType":"Hazard Ratio (HR)","paramValue":"0.84","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.0","upperLimit":"34.6","value":"25.8"},{"groupId":"OG001","lowerLimit":"29.9","upperLimit":"55.3","value":"39.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets), PO, BID along with cobimetinib, 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 960 mg (four, 240 mg tablets), PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab matching placebo as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21 and vemurafenib 960 mg (four, 240 mg tablets) PO, BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG000","title":"Arm A: Pbo + Cobi + Vem"},{"description":"Participants received vemurafenib, 960 mg (four, 240 mg tablets) PO, BID along with cobimetinib 60 mg (three, 20 mg tablets) PO, QD on Days 1 to 21 only followed by vemurafenib 720 mg (three, 240 mg tablets) PO, BID and vemurafenib matching placebo, PO, BID on Days 22 to 28 during the 28 day run-in period. During triple combination period (Cycle 1 onwards), participants received atezolizumab 840 mg as IV infusion on Days 1 and 15, cobimetinib, 60 mg (three, 20 mg tablets) PO, QD, on Days 1 to 21, vemurafenib 720 mg (three, 240 mg tablets) PO BID on Days 1 to 28, and vemurafenib placebo (1 tablet) PO BID on Days 1 to 28. Study treatment was continued until investigator determined PD, death, unacceptable toxicity, withdrawal of consent, or pregnancy, whichever occurred first.","id":"OG001","title":"Arm B: Atezo + Cobi + Vem"}],"paramType":"MEDIAN","populationDescription":"ITT population included all randomized participants, whether or not study treatment was received.","reportingStatus":"POSTED","timeFrame":"Baseline up to death due to any cause (up to approximately 85 months)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}